RANKL inhibition — for example, using denosumab, a monoclonal antibody against the receptor activator of nuclear factor‐kappa B ligand (RANKL) — might therefore provide a novel approach to the prevention and treatment of BC 36, 37. The gene discussed is TNFSF11; the disease is breast cancer.